For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new ...

October is World Blindness Awareness Month, and patients with ultra-rare eye diseases are in desperate need of a new drug ...

AI is becoming increasingly sophisticated, taking on responsibilities that were once exclusive to human beings. However, there are also disadvantages posed by ethical ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

The False Claims Act (FCA) and the Anti-Kickback Statute (AKS) are two of the Department of Justice’s (DOJ) primary tools when it comes to fighting fraud. Originally enacted during the Civil War to ...

The GLP-1 drug market is booming, fueled by their success in treating diabetes and obesity. Yet, this growth has unleashed a torrent of litigation — patent disputes, regulatory battles, and clashes ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

The number of psychedelic drug developers reaching Phase 2 and Phase 3 clinical trials is growing, in recognition of the level of unmet need in many mental health disorders and other conditions. Those ...

Conferences and trade shows are great places to learn about your competitive environment, as most companies in the industry usually attend these events; this includes competitors, suppliers, customers ...

During my stint (five years and some change) as a senior manager in PwC’s Health Research Institute, I had the opportunity to work on the pharmaceutical and life sciences sections of several Medical ...

Kelsey Mullady Unfortunately, too often organizations treat the compliance department as an afterthought and scramble to get practices into place just in time. Worse yet, many organizations silo the ...

Implementing AI in drug discovery offers significant potential for reducing operating costs, though the extent varies widely. A Deloitte report suggests AI could cut drug development costs by up to 70 ...